Literature DB >> 21372769

Peritoneal washing cytology in gastric cancer. How, when and who will get a benefit? A review.

M La Torre1, S Rossi Del Monte, M Ferri, G Cosenza, P Mercantini, V Ziparo.   

Abstract

The most frequent cause of treatment failure following surgery for gastric cancer is peritoneal metastasis. The ability to predict the likelihood of peritoneal recurrence should improve the therapeutic approach to gastric cancer. Cytological analysis of peritoneal washings is thought to be useful for direct detection of free cancer cells in the peritoneal cavity. Intraperitoneal free cancer cells (IFCC) isolated during peritoneal washing in patients with gastric cancer, have been demonstrated to be significantly and independently related to the prognosis, influencing both early recurrence and poor survival, so that since 1998 the Japanese Classification of Gastric Carcinoma (JCGC) recommend peritoneal wash cytology (PWC) for the local staging. In Western countries PWC is not uniform practice, because of several controversies regarding the low sensitivity rate of conventional cytology, the correct application of molecular diagnosis (immunostaining and RT_PCR) and the exact role of PWC in the clinical practice. The authors examine the current apply of peritoneal washing in gastric cancer, emphasizing the clinical implication of peritoneal cytology by analyzing the different modality and techniques to perform it (conventional cytology, immunocytochemistry, RT-PCR), when to achieve it during the diagnostic or clinical work-up (at the staging or during the surgical treatment), and who will get a benefit (all patients or selected patients).

Entities:  

Mesh:

Year:  2011        PMID: 21372769

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  5 in total

1.  Positive peritoneal washing cytology is a potential risk factor for the recurrence of curatively resected colorectal cancer.

Authors:  Yoichiro Homma; Takashi Hamano; Yasuhiro Akazawa; Yoshiro Otsuki; Shinichi Shimizu; Hiroshi Kobayashi; Shingo Kameoka; Yasuyuki Kobayashi
Journal:  Surg Today       Date:  2013-08-14       Impact factor: 2.549

2.  Surgery combined with chemotherapy for recurrent gastric cancer achieves better long-term prognosis.

Authors:  F Kong; Y Qi; H Liu; F Gao; P Yang; Y Li; Y Jia
Journal:  Clin Transl Oncol       Date:  2015-06-19       Impact factor: 3.405

3.  Plasma exosome-encapsulated microRNA-21 and microRNA-92a are promising biomarkers for the prediction of peritoneal recurrence in patients with gastric cancer.

Authors:  Naruyoshi Soeda; Hisae Iinuma; Yusuke Suzuki; Daisuke Tsukahara; Hironori Midorikawa; Yuichi Igarashi; Yoshimasa Kumata; Masahiro Horikawa; Takashi Kiyokawa; Takeo Fukagawa; Ryoji Fukushima
Journal:  Oncol Lett       Date:  2019-09-04       Impact factor: 2.967

4.  Risk Factors of Gastric Cancer in High-Risk Region of China: A Population-Based Case-control Study

Authors:  Ping Chen; Yulan Lin; Kuicheng Zheng; Baoying Liu; Chuancheng Wu; Wei Yan; Yuanhua Cai
Journal:  Asian Pac J Cancer Prev       Date:  2019-03-26

5.  Dose-Effect Relationship Between Gastric Cancer and Common Digestive Tract Symptoms and Diagnoses in Anhui, China.

Authors:  Mengsha Tang; Xingrong Shen; Jing Chai; Jing Cheng; Debin Wang
Journal:  Cancer Manag Res       Date:  2021-06-22       Impact factor: 3.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.